| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human General transcription factor II-I repeat domain-containing protein 2A protein was used as the immunogen for the GTF2IRD2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
The TFII-I family contains two highly homologous 949 amino acid proteins, GTF2IRD2 (also called GTF2IRD2 alpha and GTF2IRD2A) and GTF2IRD2B. Localizing to the nucleus, these proteins are ubiquitously expressed and contain two GTF2I- like repeats. Encoded by a gene mapping to human chromosome 7q11.23, GTF2IRD2 and GTF2IRD2B are located in the Williams-Beuren syndrome (WBS) critical region. The deletion of genes located within this region results in WBS, possibly due to the unequal crossing over of highly homologous low-copy repeat sequences that flank the deleted region. WBS is an autosomal dominant genetic condition that is characterized by physical, cognitive and behavioral traits including facial dysmorphology, vascular stenoses, growth deficiencies, dental anomalies and neurologic and musculoskeletal abnormalities.
This anti-GTF2IRD2 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone PCRP-GTF2IRD2-1B4, Mouse IgG2a, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: GTF2IRD2
- Format: Purified
- Localization: Nucleus
- Species reactivity: Human
- Applications (listed): FACS, WB
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone PCRP-GTF2IRD2-1B4, Mouse IgG2a
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
GTF2IRD2 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling GTF2IRD2 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link GTF2IRD2 signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- FACS
- WB
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
